Molecular anomalies in MED13L, leading to haploinsufficiency, have been reported in patients with moderate to severe intellectual disability (ID) and distinct facial features, with or without congenital heart defects. Phenotype of the patients was referred to "MED13L haploinsufficiency syndrome." Missense variants in MED13L were already previously described to cause the MED13L-related syndrome, but only in a limited number of patients. Here we report 36 patients with MED13L molecular anomaly, recruited through an international collaboration between centers of expertise for developmental anomalies. All patients presented with intellectual disability and severe language impairment. Hypotonia, ataxia, and recognizable facial gestalt were frequent findings, but not congenital heart defects. We identified seven de novo missense variations, in addition to proteintruncating variants and intragenic deletions. Missense variants clustered in two mutation hot-spots, i.e., exons 15-17 and 25-31. We found that patients carrying missense mutations had more frequently epilepsy and showed a more severe phenotype. This study ascertains missense variations in MED13L as a cause for MED13L-related intellectual disability and improves the clinical delineation of the condition.
Introduction
Mediator is a large coregulator complex conserved from yeast to humans. The complex has emerged as a master coordinator of cell lineage determination, integrating signaling from various transcription factors, epigenetic regulators and non-coding RNAs [1] . In response to various stimuli, mediator undergoes conformational changes and creates a DNA loop between activated enhancer elements and promoter, notably through interactions with cohesins [1] . Mediator physically bridges transcription factors bound at enhancer elements with the RNA polymerase II transcription machinery at core promoter regions [1] . Mediator is organized into four modules, i.e., the tail-, the middle-, the head-, and the CDK8-kinase module [2] . In vertebrates, the latter module is composed of CCNT1 and three additional proteins: CDK8, MED12, and MED13; or their respective paralogs: CDK19, MED12L, and MED13L [3] . Disease-causing variations have been identified in genes encoding the CDK8module proteins. MED12 variants cause syndromic intellectual disabilities (ID), namely Opitz-Kaveggia syndrome Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10048-018-0541-0) contains supplementary material, which is available to authorized users.
(MIM #305450), Lujan-Fryns syndrome (MIM #309520), and Ohdo syndrome (MIM #300895) [4] . CDK19 interruption by a translocation breakpoint has been found to cause moderate ID with microcephaly and retinal folds in a patient [5] . Recently, MED13L haploinsufficiency have been identified in patients with moderate to severe ID, hypotonia, and distinctive facial gestalt (OMIM #616789) [6] [7] [8] [9] [10] . The recognizable syndrome was delineated by Asadollahi et al. [7] and broadened by further reports [6, 8, [10] [11] [12] [13] [14] [15] . The gene is located on chromosome 12q24. 21 and encodes MED13L (alias TRAP240L), expressed in heart and brain tissues [9] . Originally, the interruption of MED13L by a translocation breakpoint was identified in a patient with dextro-loop transposition of the great arteries (dTGA-MIM #608808) and intellectual disability (ID). Given that association, a cohort of 97 individuals with isolated dTGA was screened for MED13L sequence variations. Rare heterozygous missense variants were identified in four patients [9] . Familial segregation was not available for three variants and showed that the remaining variant was inherited from a healthy parent [9] . Updated annotations of the four variations showed that the variant c.2056A>C was reported 472 times in GnomAD database (http://gnomad. broadinstitute.org/). Variants c.752A>G and c.6068A>G were reported in GnomAD database once and the variant c.5615G>A was reported once in 1000G database (http:// www.internationalgenome.org/). Therefore, clinical relevance of these variants remains unclear. It was hypothesized that missense variants were associated with congenital heart defects (CHDs), particularly dTGA, without intellectual disability [10] .
To date, 33 additional patients with a MED13L variants or intragenic deletion were reported [6-8, 10, 12, 13, 15-22] . The DDD studies identified at least 19 patients with a MED13L variant, highlighting MED13L as one of the most common ID-causing gene [14, 23] . Variants were either identified by targeted sequencing, indicating that the condition could be suspected prior to the molecular analysis, or by exome sequencing [12] . Strikingly, no further dTGA was found and all patients presented with ID, characteristic facial gestalt, and less commonly aspecific CHD in 6/25 cases (patent foramen ovale, Fallot tetralogy, pulmonary atresia). To our knowledge, seven missense variants were identified in 11 patients, but the lack of precise clinical data in most of them precluded clarification of their clinical relevance or possible genotypephenotype correlation [8, 13, 14, 17] . Here, we report on 36 patients with MED13L variations affecting its function, including seven missense variants in nine patients. We aim to better delineate the phenotype and discuss possible genotype-phenotype correlation.
Subjects and methods

Patients
Thirty-six patients from 35 families were recruited through an international collaboration between centers of expertise for developmental anomalies. All patients were clinically examined by a clinical geneticist. Two patients have been published previously, but more detailed information was reported here: P7 (ref. [19] ) and P8 (ref. [18] ). Informed consents were obtained for genetic tests, data sharing, and publication of patients' photographs.
Genetic analyses
Molecular investigations were performed in different diagnostic laboratories according to their routine procedure regarding testing in patients affected with ID. MED13L intragenic deletions were identified by array-CGH. MED13L sequence variants were identified by either next generation sequencing of custom gene panels designed for ID (P5, P6, P7, P8, P9, P10, P11, P23, P25, P26, P27, and P31) [19, 24] 
Results
MED13L molecular anomalies
MED13L intragenic deletions, ranging in size from 47 to 200 kb, were identified in five patients (P1, P2, P3, P4, and P24) ( Fig. 1 and Table 1 ). When available, parental segregation showed that these occurred de novo. We identified a MED13L sequence variants in 31 patients from 30 families. In one family, recurrence in two sibs (P12 and P13) was observed, presumptively due to parental germinal mosaicism. Protein-truncating variants were identified in 27 patients and were distributed all over the gene (Fig. 1a ). One proteintruncating variant, c.1708_1709del, was identified in two unrelated patients (P7-P15). [14] . All missense variations were predicted to be "probably damaging" for PolyPhen2 (score > 0.98) and deleterious" for SIFT (score < 0.03). The seven missense variants were predicted to induce substitutions involving Pro866, Pro869, Ala977, Ser2002, Thr2162, Ser2163, and Ser2177 residues, which are highly conserved across vertebrates (PhyloP score 5.69 to 6.18- Fig. 1a ). Except for Ala977, which presented a PhyloP score of 6.18, residues involved in these substitutions are also conserved in MED13, the MED13L paralog ( Fig. 1 ). Table 1 Clinical and molecular data of the 36 patients harboring likely pathogenic 
IUGR, intrauterin growth retardation
Phenotypic findings
Patient with protein-truncating mutation
Protein-truncating variants were identified in 27 patients. No remarkable prenatal history was reported and birth parameters were normal for all individuals. Motor skills were delayed, median age for independent walking being 25 months (range from 17 to 41 months). One patient did not achieve walking but he was only 32-month-old. Speech was also severely impaired in most individuals, composed of few words (16/21-52%) or even absent (5/21-24%). All patients showed moderate to severe ID. Global hypotonia was observed in 20/25 (80%) patients. Ataxia was noticed in 9/25 patients (36%), consisting mainly in dynamic ataxia and dysarthria in four patients. We did not retrieve age at onset of the cerebellar signs, but mean age of the patients with ataxia was 12 years (ranging from 2 to 39 years). One patient presented with seizures (1/26-4%). Autistic features were noticed in 5/21 (24%) cases and behavioral troubles in 10/26 (39%), consisting in aggressive behavior when specified. Brain magnetic resonance (MRI) imaging showed various non-specific anomalies comprising ventriculomegaly, myelination defect, corpus callosum anomaly, or focal cortical dysplasia ( Table 1) . Majority of the patients shared common facial features with wide open mouth, protruding tongue (without macroglossia), full cheeks, bulbous nasal tip, and horizontal eyebrows. Some patients showed thin vermilion, deep philtrum, and cupid-bow upper lip ( Fig. 2 and Table 1 ). Echocardiography revealed patent foramen ovale in two patients (P1) and pulmonary valvular stenosis in one patient (P25) (Supplemental Table 1 ).
Patient with missense variation
Missense variants were identified in nine patients. Intra-Uterine Growth Retardation (IUGR) was observed only in P33. Median age for independent walking was also 25 months (range from 18 to 30 months), but 4/9 patients (44%) were not able to walk at the age of examination (P20-P28-P33-P35). The latter patients either did not achieve independent walking (P28-P33) or achieved independent walking and then lost ability to walk because of worsening of epilepsy (P20-P35). Speech was absent in 5/9 patients (56%) and composed of few words in 4/9 patients (44%). Global hypotonia was observed in 6/9 patients (67%). Ataxia was noticed in 3/7 patients (43%). Six patients presented with seizures 6/9 patients (67%), consisting in febrile seizure (P32), late onset infantile spasms (P20) and Lennox-Gastaut syndrome (P35). Abnormal brain magnetic resonance imaging (MRI) showed various non-specific anomalies in 4/7 patients (57%), comparable with these found in patients with proteintruncating variations (supplemental Table 1 ). We observed atypical facial features in three patients (P20-P28-P35). They showed long down-slanting palpebral fissures, with everted lower eyelids (Fig. 2d ). Echocardiography revealed a patent foramen ovale in one patient (P33) ( Table 1 ).
Discussion
Here we report on a cohort of 36 patients carrying MED13L anomalies, including two previously published cases, allowing a better delineation of the associated phenotype. All individuals had motor delay, speech delay, and moderate to severe ID. In most patients, language was limited to few words or was even absent. Patients showed various degrees of cerebellar dysfunction. Ataxia was observed in 11/32 patients, and was reported especially in the older cases (P9 -P10-P13-P15-P17-P20-P23-P32-P32-P36). Since this feature was under-reported in younger patients, we hypothesize that cerebellar involvement probably worsened with age. No patient showed cerebellar anomaly on brain MRI, but repeated imaging may be needed to explore possible progressive atrophy. MRI identified aspecific features comprising myelination defects, corpus callosum abnormalities, white matter anomalies, ventriculomegaly and focal cortical dysplasia. This study confirms that most patients show a recognizable facial gestalt, which could phenotypically overlap with deletion 1p36 microdeletion syndrome (OMIM# 607872) in some patients [12] . Core facial features comprise depressed nasal bridge, horizontal eyebrows, full cheeks, and large open mouth [7, 12] . More subtle features like cupid-bow upper lip, thin vermilion border, and deep philtrum can be observed. However, in a few patients, these core facial features were absent (P22-P27). We also noticed that non-recurrent facial features can be associated, especially in patients with a missense variant located in the exon 15 (P20-P28-P35) (Fig. 2b) . In our cohort, patients were not suspected with the condition prior to genetic testing, but secondarily facial comparison allowed the description of common features. These data highlight the valuable role of clinical geneticists in the precision of the phenotype, a critical step to determine the pathogenicity of MED13L-variants.
We found only three patients with CHD, consisting in patent foramen ovale or pulmonary valvular stenosis but no complex CHD (Table 1) . Patients carried respectively MED13L intragenic deletion, splice-site variant, and missense variant (P1-P25-P33), confirming that frequency of complex CHD is less than initially expected and is not correlated with MED13L-missense variants. Concerning patients reported by Muncke et al., showing dTGA and probably no developmental delay [9] , it is unlikely that their variants affect the protein function. MED13L is located next to TBX3 and TBX5 genes. These genes respectively cause ulnar-mammary syndrome (OMIM#181450) and Holt-Oram syndrome (OMIM#142900), both conditions comprising CHD. Heart-specific enhancers have been identified within regulatory domains of both genes; however, they do not overlap with regions contacting MED13L [25] . Therefore, it is unlikely that MED13L variants could affect cis-regulatory elements controlling TBX3 or TBX5 expression during heart development. Involvement of MED13L in the dTGA of these patients remains to be explained.
We observed clinical variability, notably in patients who carried recurrent variations (P12-P13; P21-P23; P7-P15; P25-P30; P28-P35) ( Table 1) . As suggested by Asadollahi et al., we found that patients with missense variants were more prompt to develop epilepsy, compared to patients with protein-truncating variants (4/9 versus 1/26) [8] . Severe neurodevelopmental phenotype (absent speech in 5/9 versus 5/21-non ambulatory 4/9 versus 1/21) and malformations are also more frequent (Supplemental Table 1 ). More precisely, patients P20 and P35 lost the ability to walk consecutively to worsening of epilepsy. They needed gastrostomy tube feeding and P35 had hearing impairment and severe myopia. P33 showed a severe phenotype associating IUGR, absent speech, microcephaly, colobomatous microphthalmia, and never achieved sitting. Moreover, P20-P28 and P35 showed atypical facial features with long palpebral fissures and even everted lower eyelid in P20 and P35 (Fig. 2b ). Based on these particular palpebral features, P20 was initially diagnosed with Kabuki syndrome (OMIM #147920). All these data are supported by clinical features from the 11 patients reported in the literature, carrying missense variants [8, 13, 14, 17] . Clinical details of the patients reported by the DDD study were retrieved from Decipher database (https://decipher.sanger.ac.uk/) and corresponded to patients' ID: #272205, #260542, #262717, #258131, #268019, #262545, #265953, and #323183. Among them, four patients had epilepsy, and two patients had IUGR and atypical features were also noted (craniosynostosis, microcephaly, major feeding difficulties, limb malformations). Since patients with missense mutation seem to have a more severe phenotype, we could hypothesize that they induce a dominant negative effect, contrarily to protein-truncating variants. We did not consider the patient reported by Mullegama et al., who suffered from speech delay, ASD and Mediterranean fever. He carried MED13L, DEAF1, and MEFV variants [26] . Inheritance of the MED13L missense variant c.5282C>T p. (Prol1761Leu) could not be determined, since the patient was adopted. Polyphen2 and SIFT software predicted in silico that the variant was respectively benign and tolerated. There is no experimental evidence of the deleterious effect on the function of the protein. Thus, there was not enough evidence to consider the variant as the cause of the neurodevelopmental disorder of the patient.
The seven missense variants identified in this study, as well as the MED13L-missense variants previously reported in the literature, cluster in exons 15-17 and 25-31 ( Fig. 1) [8, 13, 14, 17] . Both localizations constitute hot-spots of mutations. As expected, majority of missense variations are recurrent [8] . Previously reported variants c.2597C>T p.(Pro866Leu), c.6005C>T p.(Ser2002Leu), c.6485C>T p.(Thr2162Met) were identified in three patients [8, 13, 14, 17] . We identified four novel missense variants in six patients: variant c.2605C>T p.(Pro869Ser) was identified in two patients and as well as variant c.6488C>T p.(Ser2163Leu). Variants c.2930C>T p.(Ala977Val) and c.6530C>A p.(Ser2177Tyr) were not recurrent. One of the MED13/MED13L functions is to physically link the CDK8-module to the core Mediator complex, mainly by interacting with MED19 and CDK8 [27] . Dissociation of the CDK8-module components from the core Mediator is mediated by Mediator-bound MED13/MED13L ubiquitylation and degradation [28] . Both subunits can also relay information from temporal/spatial signals or transcription factors to the RNA polymerase II machinery, thus controlling the expression of specific genes, notably genes involved in Wnt, FGF, and Rb/ E2F pathways [8] . Since all the residues involved in the substitutions are located in highly conserved across vertebrate regions and even conserved in MED13, we can assume that these residues are probably implicated in such mechanisms. Further studies are needed to unravel the deleterious mechanism induced by these molecular changes.
Conclusion
In this cohort of 36 patients with MED13L-related intellectual disability, we confirmed recognizable facial gestalt and intellectual involvement. We highlighted possible arising of progressive cerebellar signs. We did not confirm congenital heart defects as a major feature of the condition. Patients with missense variant are significantly more at risk to develop epilepsy and seemed to have a more severe phenotype, suggesting possible dominant negative effect of the missense variants. We observed clustering of missense variants in specific domains of the protein. Substitution involving the highly conserved across species residues Asp860, Pro866, Pro869, Gly1899, Ser2002, Thr2162, and Ser2163 were identified in at least two patients. Precise roles of these domains and specific residues remain to be determined to better understand molecular mechanisms underlying MED13L-related intellectual disability.
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